



**Contact:**  
Chia Soo, MD, FACS

**Location:**  
369 N. Doheny Dr.  
Beverly Hills, CA, 90211

**Email:**  
csoo@scarlesslabs.com

**Tel:**  
310-713-9978



## Company Profile

**Industry Sector:** Biotechnology

**Company Overview:** Scarless Laboratories, Inc. is a research-focused early-stage biotechnology company founded by UCLA researchers. We are developing novel drugs, biologics and medical devices for scar prevention and improvement and chronic wound healing.

Our mission at Scarless laboratories is to close the gap between minimally effective available therapies for scar and wound healing and the pressing unmet needs of the more than 100 million patients per year who are affected by scarring and the associated developmental, functional, aesthetic, and psychological difficulties if not corrected.

**Target Market(s):** Scar revision therapy and wound healing, cosmetic and reconstructive surgery, hospitals and private practice health care providers.



## Key Value Drivers

**Technology\*:** Platform technology based on a novel, first-in-class, wound healing peptide, PGP, resulting from 17 years of focused fetal wound healing research. Demonstrated proof of concept, safety, and efficacy in a number of animal models.

**Competitive Advantage:** Available therapies for scarring include OTC products and corticosteroids and are minimally effective or have unacceptable safety profiles. There are no approved drug-based therapies for improvement in scar appearance, wound tensile strength and wound healing that are both safe and effective.

**Intellectual Property:** Valuable and robust IP portfolio that comprehensively covers PGP peptides, their manufacture, composition, and use in a wide range of applications.

**Plan & Strategy:** Completing IND enabling PGP studies. On target for clinical study start by 4<sup>th</sup> Q 2016 for scar revision using injectable PGP. Scarless is interested in acquiring strategic partners for eventual commercialization. Our novel technology and its applications should make us uniquely attractive to potential partners and investors.



## Management

- **Carol Danielson, MS, DrPH**  
President and CEO
- **Chia Soo, MD, FACS**  
Founder, Board Member, and CFO
- **Kang Ting, DMD, DMedSc**  
Founder and Board Member
- **Zhong Zheng, PhD**  
Founder and CSO



## Product Pipeline-applications

- **Injectable PGP for drug applications:** e.g. acute scar revision surgery, chronic wound healing.
- **Topical PGP for drug applications:** e.g. chronic wound healing, acute and established scar reduction
- **Medical device applications:** e.g. PGP coated sutures, meshes and anti-fibrotic coatings



*Small Business Innovation Research (SBIR)*  
*Small Business Technology Transfer (STTR)*

National Institutes of Health  
Commercialization Assistance Program (NIH CAP)

